Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-EV: Enfortumab Vedotin plus Radiotherapy as Neoadjuvant Treatment for Bladder Cancer
NCT06394570Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Sep 2024
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin in bladder cancer, sponsored by UT Southwestern Medical Center. Started Sep 2024; status: recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06394570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394570.